GlassScriptPhysician profile
Ramon Hartage
NPI 1033640016
$1,646.33
in general payments reported to CMS, 2019-2025
22 companies · $909 in 2025
The $909 reported for 2025 was more than what 87% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $161 · 2024: $576 · 2025: $909.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,646.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,646.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $383.67 | 2024-2025 | Tecvayli, Talvey, Carvykti |
| Genentech USA, INC. | $168.03 | 2023-2025 | Lunsumio, Columvi, Polivy |
| Merck Sharp & Dohme LLC | $167.25 | 2023-2025 | Prevymis, Dificid, Zerbaxa |
| Incyte Corporation | $153.47 | 2024-2025 | Jakafi, Niktimvo |
| Novartis Pharmaceuticals Corporation | $85.22 | 2024 | |
| Syndax Pharmaceuticals, INC. | $73.45 | 2025 | |
| Legend Biotech USA INC. | $73.17 | 2025 | Carvykti |
| Genmab U.S., INC. | $65.66 | 2025 | Epkinly |
| Abbvie INC. | $63.95 | 2023-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $58.97 | 2025 | Ninlaro |
| Regeneron Healthcare Solutions, INC. | $50.74 | 2025 | Lynozyfic |
| Alexion Pharmaceuticals, INC. | $45.28 | 2024-2025 | Ultomiris |
| Astellas Pharma US INC | $31.80 | 2024 | Cresemba |
| Kite Pharma, INC. | $30.36 | 2024 | Yescarta |
| Adc Therapeutics America, INC. | $30.01 | 2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $26.26 | 2023 | Adcetris |
| Sanofi-Aventis U.S. LLC | $25.57 | 2025 | |
| Genzyme Corporation | $25.20 | 2023 | |
| Cerus Corporation | $22.82 | 2023 | Intercept Blood System For Platelets |
| Glaxosmithkline, LLC. | $22.59 | 2024 | Ojjaara |
| Celgene Corporation | $22.00 | 2025 | Abecma |
| Kyowa Kirin, INC. | $20.86 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramon Hartage listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.